Vioxx side-effects explained

NewsGuard 100/100 Score

Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people.

A group of scientists, led by Timothy Hla at the University of Connecticut, may now have figured out how these drugs trigger these life-threatening side-effects. The new study will be published online in the The Journal of Experimental Medicine on August 27.

The target of these drugs is an enzyme called COX-2, which is produced in response to infection or injury and releases pain- and fever-inducing byproducts. Thus blocking COX-2 reduces pain. But blocking Cox-2 in mice, according to the new study, also stimulated the production of a protein called tissue factor, or TF, which initiates blood clotting. As heart attacks and strokes are often triggered by blood clots, it is possible that the production of TF is in part responsible for the drug's adverse side-effects in humans.

In the drug-treated mice, the high levels of TF in the blood were countered by administering TF-reducing drugs. Thus it is theoretically possible to treat people safely with Vioxx and other Cox-2 inhibitors if existing TF-blocking drugs are given simultaneously.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising trend in atrial fibrillation risk over 20 years heightens concern for related heart and stroke complications